NCT02172196已完成1 期
Relative Bioavailability of Both BI 10773 and Sitagliptin After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Sitagliptin (100 mg q.d.) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
研究概览
简要总结
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and sitagliptin were determined when both drugs were given in combination compared with BI 10773 or sitagliptin given alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
- •Age 18 to 50 years (incl.)
- •BMI 18.5 to 29.9 kg/m2 (incl.)
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation
排除标准
- •Any finding of the medical examination deviating from normal and of clinical relevance. Repeated measurement of a systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs within one month or less than 10 half-lives of the respective drug prior to first study drug administration except if a relevant interaction can be ruled out
- •Participation in another trial with an investigational drug within two months prior to first study drug administration
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (average consumption of more than 30 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to the start of study)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- •A history of additional risk factors for TdP (Torsades de pointes) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
研究组 & 干预措施
Treatment sequence ABC
Experimental
- Treatment A: BI 10773 once daily from day 1 to 5
- Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
- Treatment C: Sitagliptin once daily from day 1 to 5
干预措施: BI 10773 (Drug)
Treatment sequence ABC
Experimental
- Treatment A: BI 10773 once daily from day 1 to 5
- Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
- Treatment C: Sitagliptin once daily from day 1 to 5
干预措施: Sitagliptin (Drug)
Treatment sequence CAB
Experimental
- Treatment C: Sitagliptin once daily from day 1 to 5
- Treatment A: BI 10773 once daily from day 1 to 5
- Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
干预措施: BI 10773 (Drug)
Treatment sequence CAB
Experimental
- Treatment C: Sitagliptin once daily from day 1 to 5
- Treatment A: BI 10773 once daily from day 1 to 5
- Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
干预措施: Sitagliptin (Drug)
结局指标
主要结局
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
时间窗: Days 1-8
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
时间窗: Days 1-8
次要结局
- λz,ss (terminal half-life of the analyte in plasma)(Days 1-8)
- t½,ss (terminal half-life of the analyte in plasma at steady state)(Days 1-8)
- C24,N (concentration of analyte in plasma at 24 hours post-drug administration after administration of the Nth dose)(Days 1-8)
- tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(Days 1-8)
- MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)(Days 1-8)
- CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)(Days 1-8)
- Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)(Days 1-8)
- Aet1-t2,ss (amount of analyte eliminated in urine at steady state over a uniform dosing interval τ)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- fet1-t2,ss (fraction of analyte excreted unchanged in urine at steady state over a uniform dosing interval τ)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- CLR,ss (renal clearance of the analyte at steady state)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- UGE0-24 (Urinary glucose excretion of the analyte in urine over the time interval from time zero to 24 h)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- Abnormal findings in physical examination(Baseline and within 3-10 days after last study drug administration)
- Changes from baseline in vital sings (blood pressure, pulse rate)(Baseline, day 1 and within 3-10 days after last study drug administration)
- Changes from baseline in 12-lead ECG (electrocardiogram)(Baseline and within 3-10 days after last study drug administration)
- Changes from baseline in clinical laboratory tests(Baseline, day 1, 5 and within 3-10 days after last study drug administration)
- Incidence of adverse events(up to 28 days)
- Assessment of tolerability by investigator on a 4-point scale(Within 3-10 days after last study drug administration)
研究者
相似试验
已完成
1 期
Drug-drug Interaction of Empagliflozin (BI 10773) and SimvastatinHealthyNCT01304329Boehringer Ingelheim18
已完成
1 期
Bioavailability of BI 10773 and Pioglitazone in Healthy Male VolunteersHealthyNCT02276365Boehringer Ingelheim20
已完成
1 期
Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male VolunteersHealthyNCT02172261Boehringer Ingelheim16
已完成
1 期
Relative Bioavailability BI 10773 and Metformin in Healthy Male VolunteersHealthyNCT02172248Boehringer Ingelheim16
已完成
1 期
Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy VolunteersHealthyNCT01111331Boehringer Ingelheim18